New SEC Form D filing

NextPoint Therapeutics, Inc., 2026-07-30

A new SEC Form D private-offering notice from Cambridge, MA, a $48,729,165 filer-stated offering target in Biotech. The source filing is one click away.

What this filing says

NextPoint Therapeutics, Inc. site↗ Verified via SEC Form D

Clinical stage biotech developing precision immuno-oncology therapies targeting the B7-H7 (HHLA2) checkpoint pathway for patients who do not respond to PD-1/L1 inhibitors.

Filed 2026-07-30Filed to raise $48,729,165First money in 2026-07-22Raised so far $33,728,772HQ (as filed) Cambridge, MASector Biotech web-verified against the company’s own siteStage (inferred) GrowthCall status Call-ready
Source linked the Form D on EDGAR↗Website verified nextpointtx.com↗Named in the filing 8 executives & directors

This is a public SEC Form D private-offering notice, the filer's own statement to the SEC. Amounts are offering targets, not confirmed closes. Takeoff Radar pulls Form D nightly from EDGAR and links every filing to its source.

Other Form D filings from the same week

each with its own page and its own EDGAR source